Purpose
Please note that text and guidelines are from 2025, new and updated guidelines will be available before next application round opens! The objective of this call is to broadly promote Danish clinical or translational research of high international level. The research should involve patients/humans and/or clinical practice, diagnostic or therapeutic methods, but can also involve established animal models.
Funding
A total of up to DKK 76 million is available for projects lasting from 1-3 years.
Projects of up to DKK 4,400,000 million can be applied for with a yearly maximum budget of DKK 1,480,000 million.
NNF funding is highly aligned with its core priorities:
👉 Projects outside these domains have very low success probability
Successful proposals demonstrate:
👉 NNF is highly competitive and expects top-tier scientific quality
👉 Impact is explicitly built into evaluation frameworks
👉 Increasing focus on innovation ecosystems and real-world application
High success rates are associated with:
👉 NNF frequently funds:
👉 NNF funds both:
👉 Large grants require highly structured project planning
NNF strongly values:
👉 Funding often goes to ecosystem-building initiatives
👉 Reflects global health and sustainability priorities
👉 Communication style influences reviewer perception
Highest impact factors:
Moderate predictors:
4. Translational potential
5. Investigator strength
6. Collaboration & institutional quality
Supporting factors:
7. Feasibility & planning
8. Ecosystem-building potential
9. Proposal clarity
Compared to other funders:
👉 Key evaluation question:
“Will this research create significant scientific breakthroughs AND long-term societal impact?”
The research activities applied for must be anchored at a university, hospital or other non-profit research institution in Denmark.
Only principal investigators are eligible to apply.
Eligible Countries:
Sponsor Institute/Organizations: Novo Nordisk Foundation
Sponsor Type: Corporate/Non-Profit
Address: Tuborg Havnevej 19 2900 Hellerup
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Aug 19, 2026
Aug 19, 2026
$11,997,740
DKK 76 million
Affiliation: Novo Nordisk Foundation
Address: Tuborg Havnevej 19 2900 Hellerup
Website URL: https://novonordiskfonden.dk/en/grant/projektstoette-i-klinisk-og-translationel-laegevidenskab/
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.